111 related articles for article (PubMed ID: 1606537)
21. Secondary surgery in patients with serous low malignant potential ovarian tumors with peritoneal implants.
Kane A; Uzan C; Rey A; Gouy S; Duvillard P; Morice P
Int J Gynecol Cancer; 2010 Apr; 20(3):346-52. PubMed ID: 20375795
[TBL] [Abstract][Full Text] [Related]
22. The role of DNA flow cytometry in borderline malignant ovarian tumors.
Lai CH; Hsueh S; Chang TC; Tseng CJ; Huang KG; Chou HH; Chen SM
Cancer; 1996 Aug; 78(4):794-802. PubMed ID: 8756374
[TBL] [Abstract][Full Text] [Related]
23. Prognostic significance of DNA ploidy and S-phase fraction in malignant serous cystadenocarcinoma of the ovary.
Bakshi N; Rajwanshi A; Patel F; Ganguly NK
Anal Quant Cytol Histol; 1998 Jun; 20(3):215-20. PubMed ID: 9642449
[TBL] [Abstract][Full Text] [Related]
24. [Clinicopathological evaluation on ovarian serous borderline tumours and their implants].
Guo L; Lian L; Liu T
Zhonghua Fu Chan Ke Za Zhi; 1996 May; 31(5):287-90. PubMed ID: 9206182
[TBL] [Abstract][Full Text] [Related]
25. [Clinicopathologic analysis and expression of cyclin D1 and p53 of ovarian borderline tumors and carcinomas].
Shao HL; Shen DH; Xue WC; Li Y; Yu YZ
Zhonghua Fu Chan Ke Za Zhi; 2007 Apr; 42(4):227-32. PubMed ID: 17631760
[TBL] [Abstract][Full Text] [Related]
26. Prediction of long-term survival by flow cytometric analysis of cellular DNA content in patients with advanced ovarian cancer.
Friedlander ML; Hedley DW; Swanson C; Russell P
J Clin Oncol; 1988 Feb; 6(2):282-90. PubMed ID: 3276825
[TBL] [Abstract][Full Text] [Related]
27. Image analysis of cellular DNA content in peritoneal fluid of patients with ovarian tumors of low malignant potential and invasive epithelial ovarian cancer.
Guidozzi F; Szumel RC; Ball JH; Johnston DA; Katz RL; Kidd L
Gynecol Oncol; 1996 May; 61(2):204-9. PubMed ID: 8626133
[TBL] [Abstract][Full Text] [Related]
28. [Risk factors for recurrent disease in borderline ovarian tumors].
Líbalová P; Vernerová Z; Hubicková-Heringová L; Pintérová D; Tikovský K; Kubecová M; Svoboda B
Ceska Gynekol; 2012 Feb; 77(1):31-5. PubMed ID: 22536638
[TBL] [Abstract][Full Text] [Related]
29. [Evaluation of peritoneal extensions for the diagnosis and management of serous ovarian borderline tumors].
Andrei S; Stolnicu S; Rădulescu D; Mocan S; Puşcaşu L
Rev Med Chir Soc Med Nat Iasi; 2006; 110(3):679-86. PubMed ID: 17571566
[TBL] [Abstract][Full Text] [Related]
30. Ovarian serous tumors of low malignant potential (serous borderline tumors). The relationship of exophytic surface tumor to peritoneal "implants".
Segal GH; Hart WR
Am J Surg Pathol; 1992 Jun; 16(6):577-83. PubMed ID: 1599036
[TBL] [Abstract][Full Text] [Related]
31. [Clinicopathologic analysis of ovarian serous and mucinous borderline tumors].
Zhong C; Yu X; Zhang J; Wei B; Luo B; Sun L; Zhang N; Fu Q
Zhonghua Bing Li Xue Za Zhi; 2001 Aug; 30(4):253-5. PubMed ID: 11758211
[TBL] [Abstract][Full Text] [Related]
32. Simultaneous carcinoma involving the endometrium and the ovary. A clinicopathologic, immunohistochemical, and DNA flow cytometric study of 18 cases.
Prat J; Matias-Guiu X; Barreto J
Cancer; 1991 Dec; 68(11):2455-9. PubMed ID: 1933783
[TBL] [Abstract][Full Text] [Related]
33. Prognostic factors in patients with ovarian serous low malignant potential (borderline) tumors with peritoneal implants.
Kane A; Uzan C; Rey A; Gouy S; Camatte S; Pautier P; Lhommé C; Haie-Meder C; Duvillard P; Morice P
Oncologist; 2009 Jun; 14(6):591-600. PubMed ID: 19487334
[TBL] [Abstract][Full Text] [Related]
34. Cell proliferation in ovarian carcinoma: superior accuracy of S-phase fraction (SPF) by DNA labeling index versus flow cytometric SPF, lack of independent prognostic power for SPF and DNA ploidy, and limited effect of SPF on tumor growth rate.
Meyer JS; Gersell DJ; Yim S
Gynecol Oncol; 2001 Jun; 81(3):466-76. PubMed ID: 11371140
[TBL] [Abstract][Full Text] [Related]
35. Ovarian epithelial tumors of borderline malignancy. A clinical and pathologic study of 109 cases.
Bostwick DG; Tazelaar HD; Ballon SC; Hendrickson MR; Kempson RL
Cancer; 1986 Nov; 58(9):2052-65. PubMed ID: 3756820
[TBL] [Abstract][Full Text] [Related]
36. Prognostic factors in well-differentiated early-stage epithelial ovarian cancer.
Schueler JA; Cornelisse CJ; Hermans J; Trimbos JB; van der Burg ME; Fleuren GJ
Cancer; 1993 Feb; 71(3):787-95. PubMed ID: 8431861
[TBL] [Abstract][Full Text] [Related]
37. Flow cytometric analysis of nuclear DNA content in ovarian tumors. Association of ploidy with tumor type, histologic grade, and clinical stage.
Lage JM; Weinberg DS; Huettner PC; Mark SD
Cancer; 1992 Jun; 69(11):2668-75. PubMed ID: 1571896
[TBL] [Abstract][Full Text] [Related]
38. Ovarian Low-grade Serous Carcinoma: A Clinicopathologic Study of 33 Cases With Primary Surgery Performed at a Single Institution.
Okoye E; Euscher ED; Malpica A
Am J Surg Pathol; 2016 May; 40(5):627-35. PubMed ID: 26900814
[TBL] [Abstract][Full Text] [Related]
39. Results after laparoscopic management of serous borderline tumor of the ovary with peritoneal implants.
Deffieux X; Morice P; Camatte S; Fourchotte V; Duvillard P; Castaigne D
Gynecol Oncol; 2005 Apr; 97(1):84-9. PubMed ID: 15790442
[TBL] [Abstract][Full Text] [Related]
40. Prognostic factors for patients with advanced stage serous borderline tumours of the ovary.
Morice P; Camatte S; Rey A; Atallah D; Lhommé C; Pautier P; Pomel C; Coté JF; Haie-Meder C; Duvillard P; Castaigne D
Ann Oncol; 2003 Apr; 14(4):592-8. PubMed ID: 12649107
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
